Literature DB >> 12794116

B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1.

Vrajesh V Parekh1, Durbaka V R Prasad, Pinaki P Banerjee, Bimba N Joshi, Anil Kumar, Gyan C Mishra.   

Abstract

B cells recognize Ag through their surface IgRs and present it in the context of MHC class II molecules to CD4(+) T cells. Recent evidence indicates that B cells also present exogenous Ags in the context of MHC class I to CD8(+) T cells and thus may play an important role in the modulation of CTL responses. However, in this regard, conflicting reports are available. One group of studies suggests that the interaction between B cells and CD8(+) T cells leads to the activation of the T cells, whereas other studies propose that it induces T cell tolerance. For discerning this dichotomy, we used B cells that were activated with either LPS or anti-Ig plus anti-CD40 Ab, which mimic the T-independent and T-dependent modes of B cell activation, respectively, to provide accessory signals to resting CD8(+) T cells. Our results show that, in comparison with anti-Ig plus anti-CD40 Ab-activated B cells, the LPS-activated B cells (LPS-B) failed to induce significant levels of proliferation, cytokine secretion, and cytotoxic ability of CD8(+) T cells. This hyporesponsiveness of CD8(+) T cells activated with LPS-B was significantly rescued by anti-TGF-beta1 Ab. Moreover, it was found that such hyporesponsive CD8(+) T cells activated with LPS-B had entered a state of anergy. Furthermore, LPS-B expresses a significantly higher level of TGF-beta1 on the surface, which caused the observed hyporesponsiveness of CD8(+) T cells. Therefore, this study, for the first time, provides a novel mechanism of B cell surface TGF-beta1-mediated hyporesponsiveness leading to anergy of CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794116     DOI: 10.4049/jimmunol.170.12.5897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  Regulatory B cells in autoimmunity: developments and controversies.

Authors:  Claudia Mauri; Paul A Blair
Journal:  Nat Rev Rheumatol       Date:  2010-09-21       Impact factor: 20.543

Review 3.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

4.  Abortive activation precedes functional deletion of CD8+ T cells following encounter with self-antigens expressed by resting B cells in vivo.

Authors:  Joanne M Fraser; Claire N Janicki; Ben J E Raveney; David J Morgan
Journal:  Immunology       Date:  2006-06-23       Impact factor: 7.397

Review 5.  Cytokine-producing B lymphocytes-key regulators of immunity.

Authors:  Frances E Lund
Journal:  Curr Opin Immunol       Date:  2008-04-15       Impact factor: 7.486

Review 6.  Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development.

Authors:  Sze-Wah Tse; Andrea J Radtke; Fidel Zavala
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 7.  B cells and atherosclerosis.

Authors:  Prasad Srikakulapu; Coleen A McNamara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

Review 8.  Integration of B cell responses through Toll-like receptors and antigen receptors.

Authors:  David J Rawlings; Marc A Schwartz; Shaun W Jackson; Almut Meyer-Bahlburg
Journal:  Nat Rev Immunol       Date:  2012-03-16       Impact factor: 53.106

9.  Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.

Authors:  Thomas Fehr; Fabienne Haspot; Joshua Mollov; Meredith Chittenden; Timothy Hogan; Megan Sykes
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells.

Authors:  Michael G Overstreet; Helen Freyberger; Ian A Cockburn; Yun-Chi Chen; Sze-Wah Tse; Fidel Zavala
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.